Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study)
Intrathecal ICIs for NSCLC-LM patients are safe, and the recommended dose of sintilimab is 40 mg. Intrathecal sintilimab for NSCLC-LM failed from multi-line therapies, showed potential effectiveness in some patients, and is worthy of further study.
Authors
- Tao Xin (ORCID: https://orcid.org/0000-0003-2798-5068)
- Lina Du (ORCID: https://orcid.org/0000-0002-4173-1585)
- Xiaowei Song (ORCID: https://orcid.org/0000-0003-3611-2816)
- Yang Du
- Chong Teng
- Chengjuan Fan (ORCID: https://orcid.org/0000-0003-3916-7935)
- Yanju Lv
- Siqi Man
- Jing Zhang (ORCID: https://orcid.org/0009-0004-2358-1423)
- Zhichao Zhang (ORCID: https://orcid.org/0000-0001-5001-0838)
- Guohua Wang (ORCID: https://orcid.org/0000-0001-6725-1128)
- Dayong Huang (ORCID: https://orcid.org/0000-0001-9375-6250)
- Li Li (ORCID: https://orcid.org/0009-0003-4636-9487)
- Weixi Shen
- Yuanyuan Hu (ORCID: https://orcid.org/0000-0001-9019-6198)
- Qiuying Jiang
Institutions
- Harbin Medical University (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1093/neuonc/noaf025
- Citations
- 6
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 9.11